While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
NASA's Perseverance Rover unexpectedly has discovered volcanic rock on the surface of Mars. Scientists initially had thought the rocks were sedimentary in nature.
The deadly tornadoes that devastated Kentucky and five other states last weekend have brought climate change back to forefront of the conversation. Scientists say no single weather event can be pinned to climate change alone, but this December has been unseasonably warm, and warmer temperatures can make extreme weather events more likely. Jana Houser, associate professor of meteorology at Ohio University, joined Cheddar to discuss what role climate change might have played in these deadly tornadoes, and what can be done to prevent severe weather events like this from getting even worse in the future.
Even as tech giant Google implements a vaccination mandate, charging its employees to declare their vaccine status within a time frame or risk dismissal, the federal government is tangled up in the court system trying to impose one of its own. Cindy Cohn, the executive director of the Electronic Frontier Foundation, and Harry Nelson, founder and managing partner of Nelson Hardiman LLP, joined Cheddar to debate the ethics, efficacy, and legality surrounding the issue. While Cohn noted that she thinks the federal mandate might be legally sound, her organization is also concerned with a separate question of privacy. "At EFF what we're most interested in is the digital surveillance that's going along with some of these attempts to try to track and confirm whether people are vaccinated or not," she said.
There is a new way for investors to bet on cannabis - the AdvisorShares Poseidon Dynamic Cannabis ETF targets about 20 of the biggest names in U.S. cannabis. It comes at a time when it's still difficult for investors to access the space. Cheddar News cannabis reporter Chloe Aiello spoke with co-founder and managing director for Poseidon Investment Management, Emily Paxhia.
Joellen Russell, Professor at the University of Arizona, joins Cheddar Climate to discuss how poor academic curricula and misinformation online are hindering efforts to educate children about climate change, as well as how Science Moms is providing resources to moms to help create a safer world for their children.
Another successful spaceflight is in the books for Jeff Bezos' Blue Origin. The company's third human spaceflight blasted off from Van Horn, TX. on Saturday, lasting about ten minutes from takeoff to landing. The crew, which included former NFL star and current GMA host Michael Strahan, traveled to the edge of space and experienced a few minutes of weightlessness before the capsule descended back to earth. Andrew Chanin, CEO of ProcureAM, joined Cheddar's Opening Bell to discuss the significance of the launch.
The U.S. Government is making its first major move toward encouraging nuclear energy in the U.S., as it pushes toward a sustainable future. Scott Waldman, White House reporter for Politico's E&E News joined Cheddar News to break down the developments. "There's definitely an audience for this now since we're looking at the value of nuclear in terms of climate policy," he said, regarding the prospects for bipartisan support.
Google reportedly has announced that its employees must declare their vaccination status by January 18 or face a loss of pay, administrative leave, and eventual termination.
